Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target
10/14/2026
Impact: 70
Healthcare
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Beam Therapeutics (NASDAQ: BEAM) and maintained a price target of $65 for the stock.
AI summary, not financial advice
Share: